川部 直人

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Fibrosis 76%
3. Chronic Hepatitis C 76%
4. Liver 74%
5. Hepacivirus 71%
6. Non-alcoholic Fatty Liver Disease 67%
7. Elasticity Imaging Techniques 62%
8. Interferons 57%
9. Liver Cirrhosis 48%
10. Chronic Hepatitis B 41%
11. atezolizumab 39%
12. Genotype 34%
13. Branched Chain Amino Acids 34%
14. Multicenter Studies 32%
15. Hepatitis B virus 32%
16. Sclerosing Cholangitis 31%
17. Hypoalbuminemia 31%
18. Sorafenib 30%
19. Alanine Transaminase 28%
20. Therapeutics 28%
21. Bevacizumab 27%
22. Phospholipases 25%
23. TRK 820 23%
24. Pancreatic Neoplasms 23%
25. Acoustics 22%
26. Nutrients 21%
27. ramucirumab 20%
28. Erythropoietic Protoporphyria 20%
29. Autoimmune Pancreatitis 19%
30. Extrahepatic Cholestasis 19%
31. alpha-Fetoproteins 19%
32. Virus Diseases 19%
33. Biopsy 19%
34. Retrospective Studies 19%
35. Rifaximin 18%
36. Immunoglobulin G 18%
37. Bilirubin 18%
38. Sphincter of Oddi 18%
39. Hepatitis B Antigens 17%
40. Play Therapy 17%
41. Viral Load 17%
42. Liver Failure 16%
43. Prospective Studies 16%
44. Choledocholithiasis 16%
45. Hyaluronic Acid 16%
46. Hepatitis B Surface Antigens 16%
47. Marginal Zone B-Cell Lymphoma 15%
48. Radiation 15%
49. Progression-Free Survival 15%
50. Cushing Syndrome 14%